Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation

被引:36
作者
Bachhav, Yogeshwar G. [1 ,2 ,3 ]
Patravale, Vandana B. [1 ]
机构
[1] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Bombay 400019, Maharashtra, India
[2] Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva, Switzerland
[3] Univ Lausanne, CH-1211 Geneva, Switzerland
关键词
meloxicam; gel; stability; skin permeation; skin irritation; anti-inflammatory activity; N-METHYL PYRROLIDONE; PENETRATION ENHANCERS; PHARMACOKINETICS; DELIVERY; DRUG;
D O I
10.2478/v10007-010-0020-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Skin delivery of NSAIDs offers several advantages over the oral route associated with potential side effects. In the present investigation, topical gel of meloxicam (MLX) was formulated using N-methyl pyrrolidone (NMP) as a solubilizer and Carbopol Ultrez 10 (R) as a gelling polymer. MLX gel was evaluated with respect to different physicochemical parameters such as pH, viscosity and spread-ability. Irritation potential of MLX gel was studied on rabbits. Permeation of MLX gel was studied using freshly excised rat skin as a membrane. Anti-inflammatory activity of MLX gel was studied in rats and compared with the commercial formulation of piroxicam (Pirox (R) gel, 0.5% m/m). Accelerated stability studies were carried out for MLX gel for 6 months according to ICH guidelines. MLX gel was devoid of any skin irritation in rabbits. After 12 h, cumulative permeation of MLX through excised rat skin was 3.0 +/- 1.2 mg cm(-2) with the corresponding flux value of 0.24 +/- 0.09 mg cm(-2) h(-1). MLX gel exhibited significantly higher anti-inflammatory activity in rats compared to Pirox (R) gel. Physicochemically stable and non-irritant MLX gel was formulated which could deliver significant amounts of active substance across the skin in vitro and in vivo to elicit the anti-inflammatory activity.
引用
收藏
页码:153 / 163
页数:11
相关论文
共 19 条
[1]  
[Anonymous], 2000, US PHARM 24 NAT FORM
[2]   The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption [J].
Beetge, E ;
du Plessis, J ;
Müller, DG ;
Goosen, C ;
van Rensburg, FJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 193 (02) :261-264
[3]   Formulation optimization of meloxicam sodium gel using response surface methodology [J].
Chang, Jui-Sheng ;
Huang, Yaw-Bin ;
Hou, Sen-Sen ;
Wang, Ren-Jiunn ;
Wu, Pao-Chu ;
Tsai, Yi-Hung .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 338 (1-2) :48-54
[4]   Clinical pharmacokinetics of meloxicam - A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug [J].
Davies, NM ;
Skjodt, NM .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :115-126
[5]   Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety [J].
Gates, BJ ;
Nguyen, TT ;
Setter, SM ;
Davies, NM .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (12) :2117-2140
[6]  
*INT C HARM TECHN, 2005, ICH QI R1 VAL AN PRO
[7]  
*INT C HARM TECHN, ICH TOP Q1 A R2 STAB
[8]   Effects of penetration enhancers on in vitro permeability of meloxicam gels [J].
Jantharaprapap, R. ;
Stagni, G. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 343 (1-2) :26-33
[9]   Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of Valdecoxib [J].
Joshi, M. ;
Patravale, V. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2006, 32 (08) :911-918
[10]   Nanostructured lipid carrier (NLC) based gel of celecoxib [J].
Joshi, Medha ;
Patravale, Vandana .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 346 (1-2) :124-132